Table 2.
Costing characteristics | Reviewed studies (n = 33) a |
---|---|
Costing approach | |
Micro | 22 (67) |
Gross | 5 (15) |
Micro + gross | 6 (18) |
Sources for costs and resource use | |
Patients (e.g., interviews, questionnaires) | 14 (42) |
Medical records | 13 (39) |
Hospital finance/administrative data | 16 (48) |
Government data | 16 (48) |
Insurance data | 4 (12) |
Literature | 8 (24) |
Expert opinion | 10 (30) |
Cost categories included | |
Direct medical | 33 (100) |
Direct nonmedical | 9 (27) |
Indirect | 7 (21) |
Inputs into direct medical costs b | 33 (100) |
Medical visits | 25 (76) |
Diagnostic studies/pathology | 23 (70) |
Tumor‐directed medications | 30 (91) |
Supportive medications | 13 (39) |
Surgery | 27 (82) |
Radiotherapy | 22 (67) |
Hospitalization | 26 (79) |
Imaging | 14 (42) |
Laboratory tests and blood services (electrolytes, urinalysis, complete blood count) | 22 (67) |
Palliative care | 10 (30) |
Training | 4 (12) |
Administrative/overhead costs | 9 (27) |
Unspecified medical costs | 4 (12) |
Inputs into direct nonmedical costs b , c | 9 (100) |
Food | 7 (78) |
Travel/Transportation | 9 (100) |
Accommodation | 5 (56) |
Food, transportation, or accommodation for companion | 2 (22) |
Other (e.g., child tutoring, home help) | 1 (11) |
Inputs into indirect costs b , c | 7 (100) |
Lost wages from cancer care | 7 (100) |
Lost wages from disability/premature mortality | 6 (86) |
Lost wages of companion | 5 (71) |
Data are presented as n (%).
Data from the 33 studies that estimate the cost of multiple steps in the breast cancer care pathway.
Categories are not mutually exclusive, and percentages may sum up to more than 100%.
Inputs into direct medical costs, n = 33; inputs into direct nonmedical costs, n = 9; inputs into indirect costs, n = 7.